Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 6 , ISSUE 1 ( January-June, 2016 ) > List of Articles

RESEARCH ARTICLE

Dynamic of Immune Response induced in Hepatitis B Surface Antigen-transgenic Mice Immunized with a Novel Therapeutic Formulation

JC Aguilar, Freya M Freyre Almeida, Aracelys Blanco, Heidy Trujillo, Dunia Hernández, Daymir García, José S Alba

Citation Information : Aguilar J, M Freyre Almeida F, Blanco A, Trujillo H, Hernández D, García D, S Alba J. Dynamic of Immune Response induced in Hepatitis B Surface Antigen-transgenic Mice Immunized with a Novel Therapeutic Formulation. Euroasian J Hepatogastroenterol 2016; 6 (1):25-30.

DOI: 10.5005/jp-journals-10018-1161

License: CC BY-NC 4.0

Published Online: 01-01-2016


Abstract

The development of therapeutic vaccines against chronic hepatitis B requires the capacity of the formulation to subvert a tolerated immune response as well as the evaluation of histopathological damage resulting from the treatment. In the present study, the dynamicity of induced immune response to hepatitis B surface antigen (HBsAg) was evaluated in transgenic mice that constitutively express the HBsAg gene (HBsAg-tg mice). After immunization with a vaccine candidate containing both surface (HBsAg) and core (HBcAg) antigens of hepatitis B virus (HBV), the effect of vaccination on clearance of circulating HBsAg and the potential histological alterations were examined. Transgenic (tg) and non-transgenic (Ntg) mice were immunized by intranasal (IN) and subcutaneous (SC) routes simultaneously. A control group received phosphate-buffered saline (PBS) by IN route and aluminum by SC route. Positive responses, at both humoral and cellular levels, were obtained after five immunizations in HBsAg-tg mice. Such responses were delayed and of lower intensity in tg mice, compared to vaccinated Ntg mice. Serum IgG response was characterized by a similar IgG subclass pattern. Even when HBsAg-specific CD8+ T cell responses were clearly detectable by gamma-interferon ELISPOT assay, histopathological alterations were not detected in any organ, including the liver and kidneys. Our study demonstrated, that it is possible to subvert the immune tolerance against HBsAg in tg mice, opening a window for new studies to optimize the schedule, dose, and formulation to improve the immune response to the therapeutic vaccine candidate. These results can be considered a safety proof to support clinical developments for the formulation under study.


PDF Share
  1. Chisari FV, Ferrari C. Hepatitis B Virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60
  2. The immune response during hepatitis B virus infection. J Gen Virol 2006 Jun;87(Pt 6):1439-1449
  3. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis b virus nucleocapsid antigen. Proc Natl Acad USA 1991 Dec 1;88(23):10445-10449
  4. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis Freya M Freyre Almeida et al 30 B virus nucleocapsid antigen. J Exp Med 1991 Dec 1;174(6): 1565-1570
  5. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis b virus infection. J Immunol 1990 Nov 15;145(10): 3442-3449
  6. The treatment of chronic viral hepatitis. N Engl J Med 1997 Jan 30;336(5):347-356
  7. Clinical aspects of hepatitis B virus infection. Lancet 1993 Nov 27;342(8883):1340-1344
  8. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998 Sep 1;102(5):968-975
  9. Long-term follow-up of HBsAg– positive patients treated with interferon-alpha for chronic hepatitis B. N Eng J Med 1996 May 30;334(22):1422-1427
  10. Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection. J Hepatol 2003;39 (Suppl 1):S151-S159
  11. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 1992 Jan;89(1):87-96
  12. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol 1995 Jul;23(1):98-101
  13. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immune transfer. Hepatology 1997 Jun;25(6):1497-1501
  14. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 2004 Oct;82(5):539-546
  15. HCV core protein modulates the immune response against the HBV surface antigen in mice. Biochem Biophys Res Commun 2003 Oct;310(1):59-63
  16. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol 2005 Feb;42(3):289-294
  17. Expresión del gen del antígeno de superficie del virus de la hepatitis B en ratones transgénicos. Interferón Biotecnol 1989;6(3):251-257
  18. Characterization of transgenic mice lineages II. Transgenic mice expressing HBsAg particles and showing female sterility. Acta Biotechnol 1993;13(4):373-383
  19. HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection. Int Immunol 2003 Oct;15(10):1125-1136
  20. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998 Nov 1;161(9): 4520-4529
  21. Long-term persistence of hepatitis B surface antigen and antibody induced by DNA-mediated immunization results in liver and kidney lesions in mice. Eur J Immunol 2006 Apr;36(4):875-886
  22. Formulación de antígenos del virus de la hepatitis B para la estimulación celular seguida de la inmunización terapéutica. Patent CU2009-164, 2009
  23. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci USA 2005 Dec 6;102(49):17780-17785.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.